

Published in final edited form as:

Nat Rev Microbiol. 2018 August 01; 16(8): 508–518. doi:10.1038/s41579-018-0025-0.

Controlling vector-borne disease by releasing modified mosquitoes

Heather A. Flores, Scott L. O'Neill

Institute of Vector-Borne Disease, Monash University, Clayton, Australia

Abstract

Aedes mosquito-transmitted diseases such as dengue, Zika and chikungunya, are becoming major global health emergencies while old threats such as yellow fever are re-emerging. Traditional control methods, which have focused on reducing mosquito populations through the application of insecticides or preventing breeding through removal of larval habitat, are largely ineffective, as evidenced by the increasing global disease burden. Here, we review novel mosquito population reduction and population modification approaches with a focus on control methods that are based on the release of mosquitoes, including the release of *Wolbachia*-infected mosquitos and strategies to genetically modify the vector, that are currently under development and have the potential to contribute to a reversal of the current alarming disease trends.

Introduction

Aedes aegypti is exquisitely adapted to tropical and sub-tropical cities as its preferred habitat, living and breeding within people's dwellings and the waste that accumulates around them. As tropical cities continue to grow, often outstripping the delivery of adequate infrastructure to manage either water delivery or waste removal, this mosquito has flourished. This rapid urban growth together with widespread global air travel, that enables human pathogens to travel as easily as their hosts, creates the perfect conditions for human disease to rapidly spread, as we are currently experiencing globally.

The burden of *Aedes*-transmitted disease has significantly increased over the past 50 years^{1,2}. The incidence of dengue, now the world's most common mosquito-borne viral disease, grew more than 30-fold during this period³. Dengue viruses are estimated to infect around 400 million people per year, and over half the world's population is at risk of the disease (FIG. 1)⁴.

Correspondence to: Scott L. O'Neill.

scott.oneill@monash.edu .

Author contributions

H.A.F. researched data for the article. S.L.O'N. and H.A.F. made substantial contributions to discussions of the content, wrote the article and reviewed and/or edited the manuscript before submission.

Competing interests statement

Heather A. Flores and Scott L. O'Neill work for The World Mosquito Program.

More recently, chikungunya virus emerged from Africa in the mid-2000s, spreading first across India and Asia, and then into the Americas in 2013⁵. Zika virus outbreaks occurred in the South Pacific in 2013 and the Americas in 2015⁵. Infection with Zika virus in the Americas coincided with a surge in cases of microcephaly and other congenital abnormalities. Even yellow fever, for which an effective vaccine exists, is re-emerging. Recent outbreaks started in Angola in late 2015 and the virus quickly spread to the Democratic Republic of Congo, Kenya and China⁶. In late 2016, hundreds of cases of yellow fever have been reported in Brazil⁷.

This unprecedented global emergence of viruses that are transmitted by arthropod vectors (arboviruses) is thought to be caused by a combination of human population growth, increasing globalization, a rapid rise in population-dense cities in tropical areas and major expansion of the geographic range of *A. aegypti*^{1,5,8}. Existing methods that aim to reduce disease by suppressing mosquito populations through the physical removal of breeding sites or rely on the application of insecticides targeting either larvae or adults are unable to cope in this new global context. To effectively limit or prevent future outbreaks, novel public health interventions are desperately needed³.

New vector control approaches that involve the release of mosquitoes currently fall into two broad classes: they either aim to reduce the vector population, or modify the vector to make it refractory to pathogen transmission. Reducing mosquito populations through suppression approaches is based on the intuitive assumption that as virus transmission is dependent on a bite from an infectious mosquito, reducing mosquitoes will lower transmission and disease. However, although this is clearly true if the mosquito population can be completely eliminated, the impact on disease if population suppression is only partial is much less clear. Currently, there is little experimental evidence (for example, randomised controlled trials with epidemiological endpoints) that indicates the effectiveness of imperfect mosquito suppression strategies^{9,10}.

Novel population reduction approaches involve rearing and releasing large numbers of male mosquitoes that cannot produce viable offspring when they mate with wild females. Over the course of many generations of continual release of these males, the size of the vector population should be substantially reduced, which in turn should reduce disease transmission. These methods include the sterile insect technique (SIT), the incompatible insect technique (IIT) and various genetic modification strategies (FIG 2).

By contrast, population modification approaches involve the release of both male and female mosquitoes that carry a heritable factor that reduces or blocks their ability to transmit viruses such as dengue or Zika viruses. As these mosquitoes mate with wild mosquitoes, the factor will spread through the population, effectively rendering the mosquitoes incapable of transmitting the pathogen without the need for population suppression. These approaches include the deployment of pathogen-blocking endosymbiotic bacteria *Wolbachia pipientis* (FIG. 3), and gene-drive mechanisms such as the CRISPR-Cas9 system coupled with transmission-blocking gene constructs (FIG. 4).

Before any new vector control approach can be deployed at scale, it should progress from laboratory-based proof-of-concept experiments to semi-field and then open-field releases¹¹. To achieve this, researchers must adapt the vector-control methodologies for large-scale releases, satisfy regulatory requirements and commit to investing great effort in community engagement. Strong public support is critical for adoption of any new technology, as these stakeholders have the power to help “pull” a technology to the field – or alternatively prevent its implementation. Finally, if field releases are successful, the task of demonstrating epidemiological impact for a particular technology still remains. Effective epidemiological studies require the support and involvement of the community at the trial site, approval by the government, collaboration with the existing health system and robust financial support.

In this Review, we describe, evaluate and compare novel vector-control methodologies that are based on either the modification of the mosquito population or mosquito population suppression approaches and that require the active release of modified mosquitoes. We highlight knowledge gaps and discuss lessons learned from field releases that may aid in the success of these or other approaches going forward.

Population modification approaches

Wolbachia to target virus transmission

The endosymbiotic bacterium *Wolbachia pipientis*, referred to as *Wolbachia* from here on, naturally infects an estimated 40-60% of all insect species^{12,13}. It is vertically transmitted via the host egg, and many *Wolbachia* strains manipulate host reproduction to provide an advantage to infected females – most commonly by inducing cytoplasmic incompatibility (CI). Infected females can mate successfully with both infected and uninfected males, which enables the rapid spread of *Wolbachia* throughout a population (FIG. 3B). The expression of CI also provides a method to suppress insect populations, by releasing *Wolbachia*-infected males into a population of naturally uninfected female insects, thus effectively sterilizing those females (see below, also FIG. 3A).

Recently, it was discovered that in addition to inducing CI in insects *Wolbachia* can protect its natural host *Drosophila melanogaster* from pathogenic viruses such as Drosophila C virus^{14,15}. Since that initial observation, a number of different *Wolbachia* strains were shown to prevent the transmission of a range of viruses and parasites in laboratory studies¹⁶⁻²³ by preventing pathogen replication within the insect^{16,24}

The properties of CI coupled with the inhibition of virus replication provide the basis for a novel intervention strategy against mosquito-transmitted diseases. By releasing both male and female mosquitoes that are infected with *Wolbachia* into a wild population it should be possible for *Wolbachia* to invade that population. *Wolbachia*-infected females would have a reproductive advantage compared with wild-type females owing to the induction of CI, and *Wolbachia* would naturally spread throughout the population until nearly all mosquitoes carried it. The *Wolbachia*-infected females would then have greatly reduced ability to transmit a virus to humans, and disease should decline and potentially be eliminated from communities^{25,26}.

In contrast to many insects, including many mosquito species, *A. aegypti* is not a natural host for *Wolbachia*, and therefore to use *Wolbachia* to modify a population, the bacteria must be introduced into the mosquito through microinjection and a stable colony needs to be established^{24,27}. Subsequently, it needs to be determined if *Wolbachia* can reduce the vector competence of the mosquito. To date, eight different *Wolbachia* strains have been transfected into *A. aegypti*: *wMel*, *wMelPop-CLA*, *wMelCS*, *wRi*, *wAu*, *wAlbA*, *wAlbB* and *wPip*^{24,27-30}. Importantly, it was shown that *Wolbachia* can limit the transmission of a range of human pathogens by *A. aegypti*, including dengue, Zika and chikungunya viruses^{16,17,19,24}, which suggests that this intervention could simultaneously target multiple diseases.

Using *Wolbachia* to reduce the ability of the mosquito population to transmit disease has a number of desirable attributes. The method requires the release of far fewer mosquitoes than population reduction methods such as SIT or IIT (Table I). Moreover, once *Wolbachia* are established in a population, they are expected to be maintained at a high frequency indefinitely³¹. In Australia, initial releases of *Wolbachia* infected male and female insects were undertaken for 10 weeks, and *Wolbachia* infection has persisted in wild mosquito populations at frequencies above 90%³². Therefore, mosquitoes infected with *Wolbachia* only need to be deployed once, which is in contrast to population suppression strategies (which requires the repeated deployments of modified mosquitoes as the natural vector population recovers). As a result, *Wolbachia*-based replacement strategies are cost effective and, moreover, as costs occur only for the initial deployment, donor fatigue' might be less of a problem for this approach as no ongoing recurrent funding is needed to sustain the intervention. Finally, as this method involves the release of both female and male mosquitoes, there is no need for the laborious and error-prone process of sex sorting before release.

Ongoing field trials

Currently, the World Mosquito Program (previously known as the Eliminate Dengue Program)³³ is undertaking deployments of *A. aegypti* infected with *Wolbachia* in five countries with strong community support. These studies have shown that the *wMel* strain of *Wolbachia* can quickly spread to near fixation in the wild mosquito population, and in the field sites in Australia, where this approach has been studied the longest, the frequency of the *wMel* strain in the mosquito population has remained stable since the initial deployment in 2011 at rates of around 90% or greater^{32,34}. Large-scale releases are now underway in Brazil (Niteroi and Rio de Janeiro), Colombia (Bello and Medellin) and Indonesia (Yogyakarta)³⁵ in the form of randomized cluster trials or large non-experimental deployments covering more than 2 million inhabitants each.

Work in Australia has shown that the method can be deployed successfully at low cost across small cities. Moreover, early time series observational data from these sites indicates no observations of local dengue transmission once *Wolbachia* is established in the local mosquito population³⁶. A randomised cluster trial of the method is currently in progress in Yogyakarta³³ ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT03055585), # NCT03055585). This trial, which is estimated to

finish in 2019, is expected to provide high quality epidemiological evidence on the degree of disease reduction through the use of *Wolbachia*-infected mosquitoes.

Releasing female mosquitoes is not without issue. As female mosquitoes bite, their release can be a source of discomfort for individuals. During the period of active releases, the number of female mosquitoes present in the population will temporarily increase and the community may experience higher biting pressure. The released *Wolbachia*-carrying female mosquitoes are expected to decrease, rather than increase, the transmission of arboviruses such as dengue, Zika and chikungunya viruses^{16,19,24}; however, communities need to accept an approach that superficially seems to counter years of health-promotion messages advising to kill mosquitoes. This issue needs to be addressed with strong community engagement³⁷.

Publicly available risk analyses provide confidence about the safety of the method^{33,38,39}, but some concern has been raised that *Wolbachia* infection might enhance the transmission of other pathogens. For example, it has been suggested that transient *Wolbachia* infections (that is temporary infections of *Wolbachia* injected into the body of the mosquito followed by pathogen challenge) may enhance infection rates, although not dissemination or transmission rates, of West Nile virus in the mosquito *Culex tarsalis*⁴⁰. However, in stably-transmitted *Wolbachia* infections (where the *Wolbachia* infection is stable, infects germ line tissues and is maternally transmitted by the mosquito), no enhancement of transmission of any virus, including West Nile virus, has been shown^{16–18,21,24,41–43}. Similarly, transient *Wolbachia* infections in anopheline mosquitoes have suggested that in certain contexts vector competence for infections with *Plasmodium* spp. might be enhanced^{44–46}, whereas in naturally infected anophelines vector competence is reduced^{47,48}. By contrast, natural *Wolbachia* infections of *Culex pipiens* mosquitos have been shown to increase susceptibility to infections with *Plasmodium relictum*⁴⁹. Clearly, extensive testing is needed before release to ensure that the control measure does not inadvertently exacerbate disease.

Although *Wolbachia* is a vertically transmitted endosymbiont, comparisons of host and bacterial phylogenies suggest that horizontal transmission can occur^{50,51}, leading to the concern that the introduction of *Wolbachia* to a novel host such as *A. aegypti* could result in the horizontal transfer of the bacterium to predators or other insects. Laboratory- and field-based experimental testing for horizontal transfer of *Wolbachia* from *A. aegypti* have found no evidence of transfer^{52,53}. Moreover, 40–60% of all insect species are naturally infected with *Wolbachia*^{13,54}, and it is unlikely that introducing *Wolbachia* into one more species will increase the frequency of horizontal transmission, especially when closely related, *Wolbachia*-infected mosquitoes such as *A. albopictus* and *A. notoscriptus* already inhabit the same larval habitats as *A. aegypti*. Furthermore, the fact that *A. aegypti* is not a natural host for *Wolbachia* despite shared habitats with the aforementioned species provides further support that horizontal transmission is unlikely to occur.

It has also been suggested that viruses might develop mutations over time that render them less susceptible or resistant to *Wolbachia*⁵⁵. The mechanistic basis of *Wolbachia*-mediated pathogen blocking remains to be fully elucidated, but current data suggest that multiple pathways underlie this effect, which suggest that resistance will not evolve easily^{56–58}. Moreover, assessments of field-released mosquitoes suggest that if resistance does develop,

it may not happen quickly³⁴. And even if resistance were to develop in the future, a great reduction in disease burden may have been afforded to communities in the intervening period.

Population reduction approaches

Sterile insect technique

Reducing mosquito populations has long been a focus of disease control programs with the underlying assumption that reducing the number of mosquitoes present in a population will limit the probability of transmission for viruses such as dengue or Zika. Population reduction approaches have been widely used, despite limited experimental evidence supporting the epidemiological effectiveness of these approaches¹⁰. One such method of population reduction, the SIT, involves irradiating or chemically treating male mosquitos to sterilize them. When these males are released and mate with wild females, no offspring are produced, eventually leading to a substantial decrease in population size (FIG. 2A)⁵⁹. SIT has been used to reduce mosquito populations with some success, although it has generally been more successful in other agricultural pest species^{60,61}.

Work to explore the use of SIT in *Aedes* species has begun^{62–66}, and the results of a pilot field trial have been published. One study, trialing SIT in *A. albopictus* at four different sites, found that eggs collected in ovitraps from treated areas had induced egg sterility rates of 18-68% compared to eggs from untreated areas, with two sites showing a significant reduction (50-72%)⁶⁷.

The use of SIT has a number of advantages. As females will not be released, communities should experience no increase in biting rates and therefore the intervention may be more acceptable than population modification approaches described above. It is also aligned with existing health-promotion messaging of reducing mosquito population size. Finally, if the population can be suppressed then reductions in disease transmission are expected with little chance of pathogen resistance developing.

However, the temporary nature of vector population suppression has some disadvantages. Complete elimination of a vector population in an area would require large numbers of males to be released over a long time period (Table I) – especially considering the biology of *A. aegypti* (for example, mosquito eggs can withstand drying for many months) - and unless the population is completely eliminated it is expected to recover quickly if no further control measures are in place. Similarly, migration of mosquitoes from regions other than the treatment area would spark a population resurgence. This means that SIT releases need to be repeated regularly to maintain community protection from disease. It also requires that mosquitoes are sorted by sex before release, which is not straightforward, and any females that escape sorting may be a competent disease vector. Another difficulty in using SIT is the generation of sterile males that have high fitness and are reproductively competitive with wild-type males^{65,68}. Finally, as for all suppression methods, a likely scenario is that the mosquito population is only reduced and not eliminated. Unfortunately, there are no experimental studies available that robustly measure the impact of incomplete suppression on epidemiological endpoints, and therefore the effects on disease are currently unclear.

Incompatible insect technique

A modified version of SIT, termed the IIT, can overcome the fitness costs that are associated with irradiation or chemical treatment of males by using *Wolbachia* to effectively sterilize males⁶⁹. To implement IIT, a *Wolbachia* strain is stably introduced into a colony of a mosquito species. In contrast to population modification approaches, only male mosquitoes carrying *Wolbachia* are released into a wild population to mate with wild-type females; owing to the CI induced by *Wolbachia*, no offspring can be produced. If males are released in high enough numbers, more incompatible matings will occur, and ultimately, the population collapses (FIG 3A).

IIT has a long history of field trials. In 1967, *Wolbachia* was first used as a population reduction strategy to control *Culex quinquefasciatus* in Burma⁷⁰. Subsequently, semi-field and pilot field studies of IIT have been performed for *A. albopictus* and *A. polynesiensis*^{71–73}. *Wolbachia*-infected males of the lymphatic filariasis vector, *A. polynesiensis*, were released over a thirty-week span in French Polynesia, leading to a significant decrease (17%) in egg brood-hatch success in the treated area relative to an untreated area⁷². In Kentucky (USA), *A. albopictus* males transinfected with the wPip strain of *Wolbachia* were released over a 17 week period, causing a significant decrease in the mean number of females collected, as well as a reduction in egg hatch in treated compared to untreated areas⁷³.

IIT has many advantages as a method of vector population reduction. Using *Wolbachia* to 'sterilize' males is not associated with the fitness costs that can reduce male mating competitiveness in SIT approaches⁶⁸. Depending on the strain of *Wolbachia* used, females that escape sorting and are released may have greatly reduced ability to transmit pathogens. Finally, as *Wolbachia* is naturally occurring and already ubiquitous, the public may accept this technique more easily than genetic modification or irradiation.

By contrast, the IIT still shares many of the limitations of SIT. It requires the continual release of large numbers of males to suppress the population (Table I), and migration of mosquitos from surrounding (untreated) areas will limit long-term effectiveness of this method. As only males are introduced into the environment, an effective sex-sorting system is still required. If non-negligible numbers of females are also released, *Wolbachia* could spread through a population as in a replacement approach rather than suppress it – although the probability of this is dependent on the overall fitness effects that the *Wolbachia* strain has on the vector^{31,74,75}. Although the IIT approach was tested on a small scale in pilot studies more than 50 years ago, it has yet to be shown that this approach can be scaled-up sufficiently to be an effective operational tool for disease control.

Using a combination of IIT and SIT could further reduce the need to carefully sort females from males before release. In this method, *Wolbachia*-infected mosquitoes are treated with low level irradiation, which sterilizes females whereas males are unaffected. Females that escape sex sorting and are released into the wild cannot produce offspring and therefore would not interfere with the induced CI in the population (FIG. 2B)^{76,77}. The low dose of irradiation has minimal effects on male fitness in a laboratory setting, which suggests that this combined method could be effective in the field^{76–79}.

Genetically modified mosquitoes

Although a number of transgenic systems have been developed to suppress mosquito populations, few have progressed to field releases^{80–83}. Oxitec has developed a number of transgenic approaches that are based on their Release of Insects carrying a Dominant Lethal (RIDL) methodology^{80,84}. The OX513A mosquito strain has been used most successfully to date. This mosquito strain has a tetracycline-repressible transcriptional activator (tTAV) under the control of its own binding site (TetO) creating a positive-feedback loop in which the expression of tTAV results in late-larval lethality.⁸⁴ When the mosquitoes are reared on a diet supplemented with tetracycline, it binds tTAV preventing its binding to TetO, decreasing the production of tTAV allowing the mosquitoes to thrive. When OX513A males are released into the wild and mate with wild-type females, they pass on the transgene to their offspring; owing to the lack tetracycline in their diet, the transgene is expressed leading to late-larval death (FIG. 2C)^{84–86}.

Two field studies have compared the fitness of OX513A mosquitoes to that of wild-type mosquitoes for male competitiveness⁸⁷ as well as dispersal and longevity⁸⁸. The life expectancy and maximal dispersal distance of OX513A is similar to that of wild-type mosquitoes, but the mean distance travelled is significantly lower⁸⁸.

Field releases of these mosquitoes have been performed in the Cayman Islands and Bahia, Brazil. The release of OX513A in the Cayman Islands allowed researchers to perform real-time comparisons of the effective numbers of males required to achieve a significant decrease in mosquito populations. Under their highest release ratios, they found an 80% relative reduction in treated versus untreated areas over a 23-week period⁸⁹. In Brazil, mosquitoes were released over the course of one year. A 95% reduction in the local population of *A. aegypti* was observed based on adult trapping data, and an 81% reduction based on egg trapping data⁹⁰. Currently, Oxitec is performing releases in the Cayman Islands, Panama and Brazil, with plans for substantial expansion in their Brazil release sites³⁵.

Oxitec's methodology has several advantages over traditional suppression methods. The radiation used in SIT generates dominant lethals in a non-specific manner – which can also lead to strong fitness effects and lowered mating competitiveness of males. The RIDL method specifically engineers a dominant lethal, thereby limiting off-target effects. Additionally, engineering allows for control of when the lethality is induced (that is, the presence or absence of tetracycline)⁸⁴. In contrast to the SIT, which induces lethality generally at the embryonic stage, lethality of OX513A is induced at late-larval stages⁵⁹, suggesting that although OX513A larvae ultimately die before adulthood, they still compete with wild-type larvae for food, possibly enhancing population suppression⁸⁴. Although the public may have concerns about the release of genetically modified insects, their concerns may be alleviated by the fact that the OX513A-based approach is a self-limiting technology. As the transgenic mosquitoes require tetracycline in their diet for survival, mosquitoes that carry the transgene cannot survive more than one generation in the field.

One of the biggest limitations of a RIDL technology such as the OX513A-based approach is that it requires large numbers of males to be released for successful suppression (Table

I), and this can be technologically and financially difficult. For the release of OX513A in both the Cayman Island and Brazil, the planned field site sizes had to be decreased owing to rearing limitations and a requirement to maintain a mating fraction of 50% for genetically modified males^{89,90}. This suggests that large-scale releases could be difficult to maintain. As with SIT and IIT, accurate sex sorting is required for this RIDL method. Although sex-sorting methods have become more efficient, rates of accidental release of females were previously reported to be between 0.02-0.33%⁸⁸⁻⁹⁰. For large scale releases, such as those planned in Brazil for which Oxitec estimates releases of 30-60 million males per week³⁵, this would result in the unintended daily release of thousands of females. In addition, a considerable community engagement effort to build sufficient trust for widespread deployment of genetically modified mosquitoes is required⁹¹.

Emerging technologies

A number of developing technologies exist that have not yet progressed to field trials. Numerous laboratory-based studies have shown that the use of transgenes can be effective in limiting pathogen transmission through the expression of genes that target the pathogen, or that are effective in suppressing mosquito populations by targeting genes involved in reproduction or by using sex distortion systems. Although these systems show promise, the difficulty lies in how to spread the transgenes to all mosquitoes in a population. One of the most promising methods to solve this problem is the use of transgenes to generate a gene-drive system, a strategy that was first proposed nearly 15 years ago⁹². Gene-drive systems alter normal Mendelian inheritance to greatly increase the odds that the drive system will be passed on to offspring. An effective gene-drive system could be used to establish disease inhibitors or population repressors into a population. Homing endonuclease genes (HEGs) were the initial inspiration for a gene drive system. HEGs encode proteins that recognize and cleave a 15-30 bp DNA sequence. By placing HEGs within their target sequences, the chromosome on which it was located would be resistant to cleavage. Cleavage of chromosomes that only contain the recognition site would occur, and owing to homology-directed repair (HDR) a heterozygote would be converted into a homozygote (FIG. 4A). HEGs have been developed in *Anopheles* and *Aedes* mosquitoes in proof-of-concept experiments⁹³⁻⁹⁵.

The CRISPR-Cas9 system has been used in genome-editing for a number of years in diverse organisms^{96,97}. A study showed that placing the genes that encode Cas9 and a guide RNA (gRNA) into the template used for HDR generated a mutagenic 'chain reaction' capable of gene drive (FIG. 4B)⁹⁸. Subsequent work showed that in laboratory settings, CRISPR-Cas9 could be used to spread anti-*Plasmodium falciparum* effector genes into an *Anopheles stephensi* population⁹⁹, to target genes required for female fertility in *Anopheles gambiae*¹⁰⁰, and to create a sex distortion system that targets female *A. gambiae*¹⁰¹, suggesting that that this system can be used for both population suppression and population modification (FIG. 4C, D). However, optimization of this methodology is still required before commencing field trials. The first two studies discussed above^{99,100} used the regulatory regions of the germline-specific gene *vasa* to induce the expression of Cas9 in the germline thus causing only heritable mutations. However, one study found that the expression of Cas9 was not completely restricted to the germline resulting in somatic

mutations¹⁰⁰. A second study found that maternal deposition of the Cas9 protein from the mother into the developing egg caused double-stranded DNA breaks during early embryonic development before a homologous chromosome was present as a repair template, resulting in an increase in non-homologous end joining repair (NHEJ) rather than HDR⁹⁹. Repair via NHEJ often results in mutations, or insertions or deletions of sequences which destroy the Cas9-recognition site and thus the generation of resistant alleles^{99,100}.

The CRISPR-Cas9 gene-drive method can potentially be extremely powerful. Only small numbers of the modified mosquitoes might need to be released (Table I) as the modification should drive itself throughout a population,⁹⁸ and nearly any sequence of interest can be targeted. However, similarly to HEGs, the CRISPR-Cas9 system is susceptible to developing resistance owing to mutations that can occur in the recognition site. As described above, multiple, laboratory-based studies using CRISPR-Cas9 for gene drive have reported the accumulation of mutations that led to CRISPR-resistant alleles^{98–100}, which halt the spread of any modifications throughout a population. Furthermore, based on theoretical modeling, evolution of resistance against the CRISPR-Cas9 system is inevitable^{102,103}. The emergence of resistance might be avoided, or at least prolonged, by targeting multiple sequences, by targeting conserved sequences that cannot tolerate disruption or by being more mindful of when releases occur in relation to seasonality of the vector population¹⁰². Whereas the OX513A strain is self-limiting, the CRISPR-Cas9-drive is self-promoting. The potential for uncontrolled spread of genetic modifications has caused concern among the scientific community¹⁰⁴, resulting in the publication of guidelines not only pertaining to field releases of such modified organisms but also preventing the accidental release of the modified organisms from laboratories^{104–107}.

Lessons learned

Most of the different technologies described above are still at early developmental stages, with limited examples of field releases, and only *Wolbachia*-based population modification approaches, as undertaken by the World Mosquito Program (WMP)³³, being done at operational scales in medium-sized cities. A number of lessons are being learned that generally apply to all of the approaches.

Importance of field-cage studies

Advocates of phased testing approaches have stressed the importance of preliminary testing of technologies in semi-field cages prior to open field release¹¹. The construction of these facilities is expensive and time consuming, and evidence suggests that they may not actually provide data that are more useful than data collected from small laboratory cages in regards to evaluating an approach. Even very elaborate field cages¹⁰⁸ do not mimic the true field situation. For example, semi-field cage experiments demonstrated successful establishment of the *w*MelPop strain of *Wolbachia* in a mosquito population, but it was later shown that this *Wolbachia* strain could not be established following open field releases^{24,109}. Those findings together with the expense of such preliminary testing strategies indicate that field-cage studies should be carefully considered and relevant to the question being addressed and not automatically recommended.

When the WMP first started to undertake field releases there was some concern that *Wolbachia* might spread in an uncontrolled manner. There was good evidence documenting regional^{110,111} and even global sweeps¹¹² of *Wolbachia* infections in naturally infected hosts, raising the prospect that once *Wolbachia* was released it might spread to locations that might not have approved its release. Initial field testing was done very carefully in Australia in geographically isolated areas to evaluate the ability of *Wolbachia* to spread⁷⁵. Over time it was realised that in *A. aegypti*, the spreading rates of the wMel strain of *Wolbachia* were very slow¹¹³, and the initial concern was unfounded. The current controversy around the potential uncontrolled spread of CRISPR-Cas9 gene-drive technology is injecting an even greater sense of caution into this area^{104,105,107}. The theoretical ability of gene-drive systems to spread from very small numbers of released individuals and to alter an entire wild population is of concern as we do not fully understand possible adverse consequences of such a release and may not be able to assess it prior to release. Current gene-drive methodologies do not have reversibility built into the system, so if negative consequences are observed, it would be difficult to stop the intervention from spreading. However, the emerging issues of resistance with this technology suggest that similar to *Wolbachia*-based approaches, the power of the gene drive systems that are being developed might be similarly overstated. Although there is merit in a cautious framework to evaluate and test these methods, it must be balanced against the public health need of new technologies to protect people from ongoing disease outbreaks. Testing and regulatory frameworks need to be sufficiently flexible to be able to adapt to less stringent and time consuming testing procedures if empirical evidence shows that risks are likely to be overstated. Otherwise technology that is urgently needed may be unnecessarily impeded in its adoption and use.

A common feature of all of these new vector control tools is that they rely on the release of mosquitoes into the environment to control the diseases they transmit. This requires communities to have high levels of trust to willingly participate given that the health promotion messages of decades have been based on the dangerous nature of mosquitoes and the need to kill them to reduce disease risk. Even the most robust and elegant technology will fail to be implemented if communities will not accept it. Recently, this was exemplified by the difficulties Oxitec has faced in applying the RIDL methodology in open releases in Florida where deep issues of mistrust toward GM technology, government and industry have led to open protests and stalling of testing plans of a potentially robust and useful technology⁹¹. Serious attention and resourcing is required for effective community engagement programs associated with these technologies so that trust and acceptance can be built with the communities that will be the end recipient of the technology³⁷. This engagement is costly and time consuming and needs to start early, even before a given technology is fully developed. Unfortunately, many of the scientists involved in the development of new technologies are laboratory focused specialists with little experience in field application or the principles of effective community engagement.

Conclusion

Existing vector control methods are clearly unable to cope with the unprecedented emergence and reemergence of arboviral diseases. A number of novel methods under development show promise in curbing the ability of *A. aegypti* mosquitoes to transmit

pathogens. Within the next few years we expect that the evidence for the effectiveness of these new interventions will accumulate. Critical to wide scale adoption of any of these approaches will be rigorous epidemiological evidence showing the impact on disease, not just entomological indicators. Many of these technologies are being developed by scientists that are not located in disease endemic countries. Ultimately, collaborations between scientists and governments of affected countries are needed to test and apply the technology. This requires open and authentic partnerships to be developed very early with these collaborators so that they are active participants in the development and implementation of the technology in their countries. Without their full support and ownership there is no pathway to adoption. Just as important will be the sustainability and cost effectiveness of the different approaches for disease endemic countries with limited resources for control programs. Hopefully, at least some of these technologies will prove to be cost saving for health ministries in which case adoption pathways will be more straight forward. With solid epidemiological evidence and community support, their widespread implementation might reverse the current, alarming global disease trend.

Acknowledgements

The authors are grateful to M. Woolfit for reviewing the manuscript and acknowledge funding from The Foundation for the National Institutes of Health through the Vector-Based Transmission of Control: Discovery Research (VCTR) program of the Grand Challenges in Global Health initiative of the Bill & Melinda Gates Foundation and The Wellcome Trust Award No.102591.

References

1. Gubler, DJ, Vasilakis, N. Arboviruses: Molecular Biology, Evolution and Control. Caister Academic Press; 2016. 1–6.
2. Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res. 2002; 33 :330–342. [PubMed: 12234522]
3. Pang T, Mak TK, Gubler DJ. Prevention and control of dengue-the light at the end of the tunnel. Lancet Infect Dis. 2017; 17 :e79–e87. [PubMed: 28185870]
4. Bhatt S, et al. The global distribution and burden of dengue. Nature. 2013; 496 :504–507. [PubMed: 23563266]
5. Mayer SV, Tesh RB, Vasilakis N. The emergence of arthropod-borne viral diseases: A global prospective on dengue, chikungunya and zika fevers. Acta Trop. 2017; 166 :155–163. [PubMed: 27876643]
6. Bagcchi S. Looking back at yellow fever in Angola. Lancet Infect Dis. 2017; 17 :269–270. [PubMed: 28244394]
7. Zwizwai R. Infectious disease surveillance update. Lancet Infect Dis. 2017; 17 :270.
8. Bonizzoni M, Gasperi G, Chen X, James AA. The invasive mosquito species *Aedes albopictus*: current knowledge and future perspectives. Trends Parasitol. 2013; 29 :460–468. [PubMed: 23916878]
9. Wilson AL, et al. Evidence-based vector control? Improving the quality of vector control trials. Trends Parasitol. 2015; 31 :380–390. [PubMed: 25999026]
10. Bowman LR, Donegan S, McCall PJ. Is Dengue Vector Control Deficient in Effectiveness or Evidence?: Systematic Review and Meta-analysis. PLoS Negl Trop Dis. 2016; 10 e0004551 [PubMed: 26986468]
11. Benedict M, et al. Guidance for Contained Field Trials of Vector Mosquitoes Engineered to Contain a Gene Drive System: Recommendations of a Scientific Working Group. 2008; 8 :127–166.

12. Hilgenboecker K, Hammerstein P, Schlattmann P, Telschow A, Werren JH. How many species are infected with Wolbachia? A statistical analysis of current data. *FEMS Microbiology Letters*. 2008; 281 :215–220. [PubMed: 18312577]
13. Zug R, Hammerstein P. Still a host of hosts for Wolbachia: analysis of recent data suggests that 40% of terrestrial arthropod species are infected. *PLoS ONE*. 2012; 7 e38544 [PubMed: 22685581]
14. Teixeira L, Ferreira A, Ashburner M. The bacterial symbiont Wolbachia induces resistance to RNA viral infections in *Drosophila melanogaster*. *PLoS biology*. 2008; 6 e2
15. Hedges LM, Brownlie JC, O'Neill SL, Johnson KN. Wolbachia and virus protection in insects. *Science*. 2008; 322 :702–702. [PubMed: 18974344]
16. Moreira LA, et al. A Wolbachia symbiont in *Aedes aegypti* limits infection with dengue, Chikungunya, and Plasmodium. *Cell*. 2009; 139 :1268–1278. [PubMed: 20064373]
17. Aliota MT, et al. The wMel Strain of Wolbachia Reduces Transmission of Chikungunya Virus in *Aedes aegypti*. *PLoS Negl Trop Dis*. 2016; 10 e0004677 [PubMed: 27124663]
18. Aliota MT, Peinado SA, Velez ID, Osorio JE. The wMel strain of Wolbachia Reduces Transmission of Zika virus by *Aedes aegypti*. *Scientific reports*. 2016; 6 28792 [PubMed: 27364935]
19. Dutra HLC, et al. Wolbachia Blocks Currently Circulating Zika Virus Isolates in Brazilian *Aedes aegypti* Mosquitoes. *Cell host & microbe*. 2016; 19 :771–774. [PubMed: 27156023]
20. Kambris Z, Cook PE, Phuc HK, Sinkins SP. Immune activation by life-shortening Wolbachia and reduced filarial competence in mosquitoes. *Science*. 2009; 326 :134–136. [PubMed: 19797660]
21. Joubert DA, O'Neill SL. Comparison of Stable and Transient Wolbachia Infection Models in *Aedes aegypti* to Block Dengue and West Nile Viruses. *PLoS Negl Trop Dis*. 2017; 11 e0005275 [PubMed: 28052065]
22. Blagrove MSC, Arias-Goeta C, Di Genua C, Failloux A-B, Sinkins SP. A Wolbachia wMel transinfection in *Aedes albopictus* is not detrimental to host fitness and inhibits Chikungunya virus. *PLoS Negl Trop Dis*. 2013; 7 e2152 [PubMed: 23556030]
23. Blagrove MSC, Arias-Goeta C, Failloux A-B, Sinkins SP. Wolbachia strain wMel induces cytoplasmic incompatibility and blocks dengue transmission in *Aedes albopictus*. *Proceedings of the National Academy of Sciences of the United States of America*. 2012; 109 :255–260. [PubMed: 22123944]
24. Walker T, et al. The wMel Wolbachia strain blocks dengue and invades caged *Aedes aegypti* populations. *Nature*. 2011; 476 :450–453. [PubMed: 21866159]
25. Ferguson NM, et al. Modeling the impact on virus transmission of Wolbachia-mediated blocking of dengue virus infection of *Aedes aegypti*. *Sci Transl Med*. 2015; 7 279ra37-279ra37
26. Dorigatti I, McCormack C, Nedjati-Gilani G, Ferguson NM. Using Wolbachia for Dengue Control: Insights from Modelling. *Trends Parasitol*. 2017; 34 :102–113. [PubMed: 29183717]
27. McMeniman CJ, et al. Stable introduction of a life-shortening Wolbachia infection into the mosquito *Aedes aegypti*. *Science*. 2009; 323 :141–144. [PubMed: 19119237]
28. Ant TH, Herd CS, Geoghegan V, Hoffmann AA, Sinkins SP. The Wolbachia strain wAu provides highly efficient virus transmission blocking in *Aedes aegypti*. *PLoS Pathog*. 2018; 14 e1006815 [PubMed: 29370307]
29. Xi Z, Khoo CCH, Dobson SL. Wolbachia establishment and invasion in an *Aedes aegypti* laboratory population. *Science*. 2005; 310 :326–328. [PubMed: 16224027]
30. Fraser JE, et al. Novel Wolbachia-transfected *Aedes aegypti* mosquitoes possess diverse fitness and vector competence phenotypes. *PLoS Pathog*. 2017; 13 e1006751 [PubMed: 29216317]
31. Turelli M. Cytoplasmic incompatibility in populations with overlapping generations. *Evolution*. 2010; 64 :232–241. [PubMed: 19686264]
32. Hoffmann AA, et al. Stability of the wMel Wolbachia Infection following invasion into *Aedes aegypti* populations. *PLoS Negl Trop Dis*. 2014; 8 e3115 [PubMed: 25211492]
33. [Accessed: 3rd September 2017] Eliminate Dengue Program. Available at:<http://www.eliminatedengue.com>

34. Frentiu FD, et al. Limited dengue virus replication in field-collected *Aedes aegypti* mosquitoes infected with *Wolbachia*. *PLoS Negl Trop Dis*. 2014; 8 e2688 [PubMed: 24587459]
35. Servick K. Winged warriors. *Science*. 2016; 354 :164–167. [PubMed: 27738153]
36. [Accessed: 9 April 2018] Queensland Health: Dengue outbreaks. Available at: <https://www.health.qld.gov.au/clinical-practice/guidelines-procedures/diseases-infection/diseases/mosquito-borne/dengue/dengue-outbreaks>
37. Kolopack PA, Parsons JA, Lavery JV. What makes community engagement effective?: Lessons from the Eliminate Dengue Program in Queensland Australia. *PLoS Negl Trop Dis*. 2015; 9 e0003713 [PubMed: 25875485]
38. De Barro PJ, Murphy B, Jansen CC, Murray J. The proposed release of the yellow fever mosquito, *Aedes aegypti* containing a naturally occurring strain of *Wolbachia pipiensis*, a question of regulatory responsibility. *Journal für Verbraucherschutz und Lebensmittelsicherheit*. 2011; 6 :33–40.
39. Murray JV, Jansen CC, De Barro P. Risk Associated with the Release of *Wolbachia*-Infected *Aedes aegypti* Mosquitoes into the Environment in an Effort to Control Dengue. *Front Public Health*. 2016; 4 :43. [PubMed: 27047911]
40. Dodson BL, et al. *Wolbachia* enhances West Nile virus (WNV) infection in the mosquito *Culex tarsalis*. *PLoS Negl Trop Dis*. 2014; 8 e2965 [PubMed: 25010200]
41. Joubert DA, et al. Establishment of a *Wolbachia* Superinfection in *Aedes aegypti* Mosquitoes as a Potential Approach for Future Resistance Management. *PLoS Pathog*. 2016; 12 e1005434 [PubMed: 26891349]
42. Glaser RL, Meola MA. The native *Wolbachia* endosymbionts of *Drosophila melanogaster* and *Culex quinquefasciatus* increase host resistance to West Nile virus infection. *PLoS ONE*. 2010; 5 e11977 [PubMed: 20700535]
43. Micieli MV, Glaser RL. Somatic *Wolbachia* (Rickettsiales: Rickettsiaceae) levels in *Culex quinquefasciatus* and *Culex pipiens* (Diptera: Culicidae) and resistance to West Nile virus infection. *J Med Entomol*. 2014; 51 :189–199. [PubMed: 24605469]
44. Hughes GL, Vega-Rodriguez J, Xue P, Rasgon JL. *Wolbachia* strain wAlbB enhances infection by the rodent malaria parasite *Plasmodium berghei* in *Anopheles gambiae* mosquitoes. *Appl Environ Microbiol*. 2012; 78 :1491–1495. [PubMed: 22210220]
45. Murdock CC, Blanford S, Hughes GL, Rasgon JL, Thomas MB. Temperature alters *Plasmodium* blocking by *Wolbachia*. *Scientific reports*. 2014; 4 :3932. [PubMed: 24488176]
46. Hughes GL, Rivero A, Rasgon JL. *Wolbachia* can enhance *Plasmodium* infection in mosquitoes: implications for malaria control? *PLoS Pathog*. 2014; 10 e1004182 [PubMed: 25187984]
47. Shaw WR, et al. *Wolbachia* infections in natural *Anopheles* populations affect egg laying and negatively correlate with *Plasmodium* development. *Nat Commun*. 2016; 7 11772 [PubMed: 27243367]
48. Gomes FM, et al. Effect of naturally occurring *Wolbachia* in *Anopheles gambiae* s.l. mosquitoes from Mali on *Plasmodium falciparum* malaria transmission. *Proceedings of the National Academy of Sciences of the United States of America*. 2017; 114 :12566–12571. [PubMed: 29114059]
49. Zélé F, et al. *Wolbachia* increases susceptibility to *Plasmodium* infection in a natural system. *Proceedings Biological sciences*. 2014; 281 20132837–20132837 [PubMed: 24500167]
50. Vavre F, Fleury F, Lepetit D, Fouillet P, Boulétreau M. Phylogenetic evidence for horizontal transmission of *Wolbachia* in host-parasitoid associations. *Mol Biol Evol*. 1999; 16 :1711–1723. [PubMed: 10605113]
51. Ahmed MZ, Breinholt JW, Kawahara AY. Evidence for common horizontal transmission of *Wolbachia* among butterflies and moths. *BMC evolutionary biology*. 2016; 16 :118. [PubMed: 27233666]
52. Popovici J, et al. Assessing key safety concerns of a *Wolbachia*-based strategy to control dengue transmission by *Aedes* mosquitoes. *Memorias do Instituto Oswaldo Cruz*. 2010; 105 :957–964. [PubMed: 21225190]
53. Hurst TP, et al. Impacts of *Wolbachia* infection on predator-prey relationships: evaluating survival and horizontal transfer between wMelPop infected *Aedes aegypti* and its predators. *J Med Entomol*. 2012; 49 :624–630. [PubMed: 22679870]

54. Hilgenboecker K, Hammerstein P, Schlattmann P, Telschow A, Werren JH. How many species are infected with *Wolbachia*?--A statistical analysis of current data. *FEMS Microbiol Lett.* 2008; 281 :215–220. [PubMed: 18312577]
55. McGraw EA, O'Neill SL. Beyond insecticides: new thinking on an ancient problem. *Nat Rev Microbiol.* 2013; 11 :181–193. [PubMed: 23411863]
56. Caragata EP, et al. Dietary cholesterol modulates pathogen blocking by *Wolbachia*. *PLoS Pathog.* 2013; 9 e1003459 [PubMed: 23825950]
57. Rancès E, Ye YH, Woolfit M, McGraw EA, O'Neill SL. The relative importance of innate immune priming in *Wolbachia*-mediated dengue interference. *PLoS Pathog.* 2012; 8 e1002548 [PubMed: 22383881]
58. Terradas G, Joubert DA, McGraw EA. The RNAi pathway plays a small part in *Wolbachia*-mediated blocking of dengue virus in mosquito cells. *Scientific reports.* 2017; 7 43847 [PubMed: 28262718]
59. Black WC, Alphey L, James AA. Why RIDL is not SIT. *Trends Parasitol.* 2011; 27 :362–370. [PubMed: 21659002]
60. Weidhaas DE, Breeland SG, Lofgren CS, Dame DA, Kaiser R. Release of chemosterilized males for the control of *Anopheles albimanus* in El Salvador. IV. Dynamics of the test population. *Am J Trop Med Hyg.* 1974; 23 :298–308. [PubMed: 4817675]
61. Dame DA, et al. Release of chemosterilized males for the control of *Anopheles albimanus* in El Salvador. II. Methods of rearing, sterilization, and distribution. *Am J Trop Med Hyg.* 1974; 23 :282–287. [PubMed: 4817673]
62. Boyer S, Gilles J, Merancienne D, Lemperiere G, Fontenille D. Sexual performance of male mosquito *Aedes albopictus*. *Med Vet Entomol.* 2011; 25 :454–459. [PubMed: 21605147]
63. [Accessed: 24 May 2017] IAEA FACTSHEET: The Zika Virus Mosquitoes How can the sterile insect technique help?. Available at:<https://www.iaea.org/sites/default/files/16/11/zika-virus-mosquitos-how-can-sterile-insect-technique-help.pdf>
64. Bellini R, et al. Dispersal and survival of *Aedes albopictus* (Diptera: Culicidae) males in Italian urban areas and significance for sterile insect technique application. *J Med Entomol.* 2010; 47 :1082–1091. [PubMed: 21175057]
65. Bellini R, et al. Mating competitiveness of *Aedes albopictus* radio-sterilized males in large enclosures exposed to natural conditions. *J Med Entomol.* 2013; 50 :94–102. [PubMed: 23427657]
66. Balestrino F, et al. Gamma ray dosimetry and mating capacity studies in the laboratory on *Aedes albopictus* males. *J Med Entomol.* 2010; 47 :581–591. [PubMed: 20695273]
67. Bellini R, Medici A, Puggioli A, Balestrino F, Carrieri M. Pilot field trials with *Aedes albopictus* irradiated sterile males in Italian urban areas. *J Med Entomol.* 2013; 50 :317–325. [PubMed: 23540120]
68. Atyame CM, et al. Comparison of Irradiation and *Wolbachia* Based Approaches for Sterile-Male Strategies Targeting *Aedes albopictus*. *PLoS ONE.* 2016; 11 e0146834 [PubMed: 26765951]
69. Bourtzis K, et al. Harnessing mosquito-*Wolbachia* symbiosis for vector and disease control. *Acta Trop.* 2014; 132 (Suppl) :S150–63. [PubMed: 24252486]
70. Laven H. Eradication of *Culex pipiens fatigans* through cytoplasmic incompatibility. *Nature.* 1967; 216 :383–384. [PubMed: 4228275]
71. Chambers EW, Hapairai L, Peel BA, Bossin H, Dobson SL. Male mating competitiveness of a *Wolbachia*-introgressed *Aedes polynesiensis* strain under semi-field conditions. *PLoS Negl Trop Dis.* 2011; 5 e1271 [PubMed: 21829750]
72. O'Connor L, et al. Open release of male mosquitoes infected with a *wolbachia* biopesticide: field performance and infection containment. *PLoS Negl Trop Dis.* 2012; 6 e1797 [PubMed: 23166845]
73. Mains JW, Brelsfoard CL, Rose RI, Dobson SL. Female Adult *Aedes albopictus* Suppression by *Wolbachia*-Infected Male Mosquitoes. *Scientific reports.* 2016; 6 33846 [PubMed: 27659038]
74. Barton NH, Turelli M. Spatial waves of advance with bistable dynamics: cytoplasmic and genetic analogues of Allee effects. *Am Nat.* 2011; 178 :E48–75. [PubMed: 21828986]
75. Hoffmann AA, et al. Successful establishment of *Wolbachia* in *Aedes* populations to suppress dengue transmission. *Nature.* 2011; 476 :454–457. [PubMed: 21866160]

76. Zhang D, Zheng X, Xi Z, Bourtzis K, Gilles JRL. Combining the sterile insect technique with the incompatible insect technique: I-impact of wolbachia infection on the fitness of triple- and double-infected strains of *Aedes albopictus*. *PLoS ONE*. 2015; 10 e0121126 [PubMed: 25849812]
77. Brelsfoard CL, St Clair W, Dobson SL. Integration of irradiation with cytoplasmic incompatibility to facilitate a lymphatic filariasis vector elimination approach. *Parasit Vectors*. 2009; 2 :38. [PubMed: 19682363]
78. Zhang D, Lees RS, Xi Z, Gilles JRL, Bourtzis K. Combining the Sterile Insect Technique with Wolbachia-Based Approaches: II--A Safer Approach to *Aedes albopictus* Population Suppression Programmes, Designed to Minimize the Consequences of Inadvertent Female Release. *PLoS ONE*. 2015; 10 e0135194 [PubMed: 26252474]
79. Zhang D, Lees RS, Xi Z, Bourtzis K, Gilles JRL. Combining the Sterile Insect Technique with the Incompatible Insect Technique: III-Robust Mating Competitiveness of Irradiated Triple Wolbachia-Infected *Aedes albopictus* Males under Semi-Field Conditions. *PLoS ONE*. 2016; 11 e0151864 [PubMed: 26990981]
80. Wise de Valdez MR, et al. Genetic elimination of dengue vector mosquitoes. *Proceedings of the National Academy of Sciences of the United States of America*. 2011; 108 :4772–4775. [PubMed: 21383140]
81. Fu G, et al. Female-specific flightless phenotype for mosquito control. *Proceedings of the National Academy of Sciences of the United States of America*. 2010; 107 :4550–4554. [PubMed: 20176967]
82. Heinrich JC, Heinrich JC, Scott MJ, Scott MJ. A repressible female-specific lethal genetic system for making transgenic insect strains suitable for a sterile-release program. *Proceedings of the National Academy of Sciences of the United States of America*. 2000; 97 :8229–8232. [PubMed: 10890889]
83. Labbé GMC, Scaife S, Morgan SA, Curtis ZH, Alphey L. Female-specific flightless (fsRIDL) phenotype for control of *Aedes albopictus*. *PLoS Negl Trop Dis*. 2012; 6 e1724 [PubMed: 22802980]
84. Phuc HK, et al. Late-acting dominant lethal genetic systems and mosquito control. *BMC Biol*. 2007; 5 :11. [PubMed: 17374148]
85. Massonnet-Bruneel B, et al. Fitness of transgenic mosquito *Aedes aegypti* males carrying a dominant lethal genetic system. *PLoS ONE*. 2013; 8 e62711 [PubMed: 23690948]
86. Bargielowski I, Nimmo D, Alphey L, Koella JC. Comparison of life history characteristics of the genetically modified OX513A line and a wild type strain of *Aedes aegypti*. *PLoS ONE*. 2011; 6 e20699 [PubMed: 21698096]
87. Harris AF, et al. Field performance of engineered male mosquitoes. *Nat Biotechnol*. 2011; 29 :1034–1037. [PubMed: 22037376]
88. Lacroix R, et al. Open field release of genetically engineered sterile male *Aedes aegypti* in Malaysia. *PLoS ONE*. 2012; 7 e42771 [PubMed: 22970102]
89. Harris AF, et al. Successful suppression of a field mosquito population by sustained release of engineered male mosquitoes. *Nat Biotechnol*. 2012; 30 :828–830. [PubMed: 22965050]
90. Carvalho DO, et al. Suppression of a Field Population of *Aedes aegypti* in Brazil by Sustained Release of Transgenic Male Mosquitoes. *PLoS Negl Trop Dis*. 2015; 9 e0003864 [PubMed: 26135160]
91. Bloss CS, Stoler J, Brouwer KC, Bietz M, Cheung C. Public Response to a Proposed Field Trial of Genetically Engineered Mosquitoes in the United States. *JAMA*. 2017; 318 :662–664. [PubMed: 28810013]
92. Burt A. Site-specific selfish genes as tools for the control and genetic engineering of natural populations. *Proceedings Biological sciences*. 2003; 270 :921–928. [PubMed: 12803906]
93. Traver BE, Anderson MAE, Adelman ZN. Homing endonucleases catalyze double-stranded DNA breaks and somatic transgene excision in *Aedes aegypti*. *Insect Mol Biol*. 2009; 18 :623–633. [PubMed: 19754740]
94. Windbichler N, et al. A synthetic homing endonuclease-based gene drive system in the human malaria mosquito. *Nature*. 2011; 473 :212–215. [PubMed: 21508956]

95. Chan Y-S, et al. The design and in vivo evaluation of engineered I-OnuI-based enzymes for HEG gene drive. *PLoS ONE*. 2013; 8 e74254 [PubMed: 24040217]
96. Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. *Science*. 2014; 346 :1258096-1258096 [PubMed: 25430774]
97. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. *Cell*. 2014; 157 :1262–1278. [PubMed: 24906146]
98. Gantz VM, Bier E. Genome editing. The mutagenic chain reaction: a method for converting heterozygous to homozygous mutations. *Science*. 2015; 348 :442–444. [PubMed: 25908821]
99. Gantz VM, et al. Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito *Anopheles stephensi*. *Proceedings of the National Academy of Sciences of the United States of America*. 2015; 112 :E6736–43. [PubMed: 26598698]
100. Hammond A, et al. A CRISPR-Cas9 gene drive system targeting female reproduction in the malaria mosquito vector *Anopheles gambiae*. *Nat Biotechnol*. 2016; 34 :78–83. [PubMed: 26641531]
101. Galizi R, et al. A CRISPR-Cas9 sex-ratio distortion system for genetic control. *Scientific reports*. 2016; 6 31139 [PubMed: 27484623]
102. Unckless RL, Clark AG, Messer PW. Evolution of Resistance Against CRISPR/Cas9 Gene Drive. *Genetics*. 2017; 205 :827–841. [PubMed: 27941126]
103. Reed FA. CRISPR/Cas9 Gene Drive: Growing Pains for a New Technology. *Genetics*. 2017; 205 :1037–1039. [PubMed: 28270527]
104. Esvelt KM, Smidler AL, Catteruccia F, Church GM. Concerning RNA-guided gene drives for the alteration of wild populations. *eLife*. 2014; 3 20131071
105. Akbari OS, et al. BIOSAFETY. Safeguarding gene drive experiments in the laboratory. *Science*. 2015; 349 :927–929. [PubMed: 26229113]
106. Okumu F, et al. Results from the Workshop ‘Problem Formulation for the Use of Gene Drive in Mosquitoes’. *Am J Trop Med Hyg*. 2017; 96 :530–533. [PubMed: 27895273]
107. National Academies of Sciences, EngineeringMedicine. *Gene Drives on the Horizon: Advancing Science, Navigating Uncertainty, and Aligning Research with Public Values*. National Academies Press; 2016.
108. Ritchie SA, et al. A Secure Semi-Field System for the Study of *Aedes aegypti*. *PLoS Negl Trop Dis*. 2011; 5 e988 [PubMed: 21445333]
109. Nguyen TH, et al. Field evaluation of the establishment potential of wMelPop *Wolbachia* in Australia and Vietnam for dengue control. *Parasit Vectors*. 2015; 8 :563. [PubMed: 26510523]
110. Turelli M, Hoffmann AA. Rapid spread of an inherited incompatibility factor in California *Drosophila*. *Nature*. 1991; 353 :440–442. [PubMed: 1896086]
111. Kriesner P, Hoffmann AA, Lee SF, Turelli M, Weeks AR. Rapid Sequential Spread of Two *Wolbachia* Variants in *Drosophila simulans*. *PLoS Pathog*. 2013; 9 e1003607 [PubMed: 24068927]
112. Riegler M, Sidhu M, Miller WJ, O'Neill SL. Evidence for a global *Wolbachia* replacement in *Drosophila melanogaster*. *Curr Biol*. 2005; 15 :1428–1433. [PubMed: 16085497]
113. Schmidt TL, et al. Local introduction and heterogeneous spatial spread of dengue-suppressing *Wolbachia* through an urban population of *Aedes aegypti*. *PLoS biology*. 2017; 15 e2001894 [PubMed: 28557993]
114. [Accessed: 1st September 2017] Debug Fresno, our first US field study. Available at:<https://blog.verily.com/2017/07/debug-fresno-our-first-us-field-study.html>

Glossary

Aedes aegypti

Aedes aegypti is the primary mosquito vector of epidemic transmission for viruses, such as dengue, zika and chikungunya. *A. aegypti* occurs primarily in tropical and sub-tropical regions of the world and is particularly adapted to urban habitats.

Wolbachia pipientis

A naturally occurring bacterial endosymbiont that is estimated to be present in 40-60% of all insect species. Commonly referred to as just *Wolbachia*.

Sterile insect technique

The radiation or chemical treatment of male mosquitos, which renders them sterile. When they are released in the field and they mate with wild-type females they cannot produce offspring.

incompatible insect technique

The release of *Wolbachia*-infected males, which when mated with wildtype females who contain no *Wolbachia* or a different, incompatible strain of *Wolbachia*, produce no offspring due to cytoplasmic incompatibility.

CRISPR-Cas9

A genome editing tool that was developed from adaptive immune systems found in bacteria and archaea. The system is composed of a nuclease, Cas9, and a guide RNA which targets the nuclease to a specific DNA sequence for cleavage.

Cytoplasmic incompatibility

When *Wolbachia*-infected male mosquitos mate with uninfected females, the resulting progeny die during early embryogenesis. If the female is also infected with the same *Wolbachia strain*, that infection can rescue the embryonic lethality resulting in viable progeny.

Vector competence

A measure of ability of arthropod vectors to acquire and transmit viruses in their saliva.

Ovitrap

Traps designed for the collection of mosquito eggs.

Homing endonuclease genes

Selfish genetic elements encoding endonucleases that recognize a specific DNA sequence and catalyse a break, which is then naturally repaired through homologous repair.

Homology-directed repair

A repair mechanisms of a DNA double-strand break, whereby the homologous chromosome is used as a template for repair.

Non-homologous end joining repair

A repair mechanism for DNA double-strand breaks, whereby the two DNA ends are ligated without the need for a homologous template, often resulting in small indels or the introduction of mutations.




Figure 1. The global distribution and burden of dengue

Evidence consensus map showing the complete absence to complete presence of dengue. Green colours indicate evidence consensus towards absence of dengue, and orange and red colours indicate consensus towards presence of dengue. Darker colouring indicates more data supporting a conclusion about the presence or absence of dengue in a country. Figure adapted from ref ⁴.




Figure 2. Modification of vectors for population reduction

New vector control approaches that involve the release of mosquitoes aim to reduce the vector population. A) In the sterile insect technique (SIT) approach, male insects are exposed to either irradiation or sterilizing chemicals, causing large-scale random damage to the insect chromosomes or dominant-lethal mutations in the sperm. These males are then released in the wild population, and when they mate with wild females, viable offspring are rarely produced, eventually leading to a substantial decrease in vector population size. B) In the incompatible insect technique approach, a *Wolbachia* strain is stably introduced into a colony of a mosquito species. Only *Wolbachia*-infected males are released, which when mated to females that do not harbour the same *Wolbachia* strain or that do not carry *Wolbachia*, results in the death of their offspring due to CI. A combination of IIT and SIT could be used to suppress mosquito populations. During this approach, *Wolbachia*-infected mosquitoes are treated with low level irradiation. As in IIT alone, *Wolbachia*-males mating with wild females will not produce offspring. In the case of accidental female releases, these irradiated females are sterile and cannot reproduce with wild or *Wolbachia*-infected males. C) RIDL (Release of Insects carrying a Dominant Lethal) is a suppression strategy, whereby males that carry a transgene that causes late-acting lethality are released in the open field. These males mate with wild-type females, and the resulting offspring die before reaching the pupal stage.




Figure 3. *Wolbachia* use for population reduction and modification approaches

A) Using *Wolbachia* in the incompatible insect technique (IIT) approach, results in population reduction. In IIT, a *Wolbachia* strain is stably introduced into a colony of a mosquito species. Only *Wolbachia*-infected males are released, which when mated to females that do not harbour the same *Wolbachia* strain or that do not carry *Wolbachia*, results in the death of their offspring due to CI. Large numbers of males are released to increase the number of incompatible matings that are occurring. Over time, the population of disease-competent mosquitoes will decrease. B) *Wolbachia* can also be used to modify

a mosquito population. Both *Wolbachia*-infected male and female mosquitoes are generally released over a 12-16 week period. CI provides a reproductive advantage to *Wolbachia*-infected females resulting in the spread and establishment of *Wolbachia* in the population. These *Wolbachia*-infected females are resistant to arboviruses such as dengue, Zika, and chikungunya.




Figure 4. Gene-drive approaches for population modification and reduction

A) Homing endonuclease genes (HEGs) encode endonuclease genes that recognize a specific DNA sequence and catalyse a break, which is then naturally repaired through homology-directed repair resulting in non-Mendelian inheritance. B) The CRISPR-Cas9 system is analogous to HEGs; however, a guide RNA (gRNA) provides sequence specificity for DNA cleavage by the Cas9 nuclease which is then repaired through homology-directed repair. Examples of CRISPR-Cas9 used in population modification and reduction approaches include C) the addition of vector competence genes with the Cas9-gRNA construct resulting in virus-resistant offspring⁹⁹, D) creating a gRNA to targeting female fertility genes resulting in sterile females¹⁰⁰, and creating a gRNA to target X-chromosome-specific sequences resulting in a reduction of female offspring¹⁰¹. The Cas9-gRNA constructs inherited by any surviving offspring resulting in its continual spread.

Table 1
Comparison of different vector control technologies that are currently being developed

Technology	Laboratory proof-of-concept	Field release	Scaled deployment beyond 50 km ²	Reapplication required	Approximate release rate (mosquitoes/ha/week)
<u>Population modification</u>					
<i>Wolbachia</i>	+	+	+	No	10-100 ^{75,109}
CRISPR-Cas9	+	-	-	No	<1
<u>Population suppression</u>					
SIT	+	+	-	Yes	1,000 ^{*67}
IIT (<i>Wolbachia</i>)	+	+	-	Yes	1,000-10,000 ^{*72,73,114}
RIDL	+	+	-	Yes	25,000-50,000 ^{*35,90}

* males/ha/week